Drug Profile
Research programme: antibacterials - MorphoSys/Daiichi Sankyo
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; MorphoSys
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Nosocomial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Nosocomial-infections in Japan
- 27 Oct 2009 Early research in Nosocomial infections in Japan (unspecified route)